Toward an off-the-shelf vaccine for B-cell malignancies

Blood

Volumn 120, Issue 8, 2012, Pages 1539-1540

  Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HLA A2 ANTIGEN; ONCOPROTEIN; T CELL LYMPHOMA 1 ONCOPROTEIN; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; CELL EXPANSION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY; VACCINE PRODUCTION;

EID: 84865431130     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-435123     Document Type: Note

References (8)

1. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5(10):1171-1177. (Pubitemid 29474422)
2. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011;29(20):2787-2794.
3. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. NEngl J Med. 2010;363(5):411-422.
4. Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res. 2011;17(12):3884-3891.
5. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebocontrolled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2007;25 (18S):Abstract 7554.
6. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099-1105.
7. Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol. 2011;137(9):1337-1342.
8. Weng J, Rawal S, Chu F, et al. TCL1: a shared tumorassociated antigen for immunotherapy against B-cell lymphomas. Blood. 2012;120(8):1613-1623.